section name header

Pronunciation

ter-i-PAR-a-tide

Classifications

Therapeutic Classification: hormones

Pharmacologic Classification: parathyroid hormones (rDNA origin)

Indications

REMS


Action

  • Regulates calcium and phosphate metabolism in bone and kidney by binding to specific cell receptors; stimulates osteoblastic activity.
  • Increases serum calcium and decreases serum phosphorus.
Therapeutic effects:
  • Increased bone mineral density with reduced risk of fractures.

Pharmacokinetics

Absorption: Extensively absorbed after SUBQ administration.

Distribution: Unknown.

Metabolism/Excretion: Metabolized by the liver; metabolites renally excreted.

Half-Life: 1 hr (after SUBQ use).

Time/Action Profile

(effects on serum calcium concentrations)

ROUTEONSETPEAKDURATION
SUBQ2 hr4–6 hr16–24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: orthostatic hypotension

F and E: calciphylaxis, hypercalcemia

MS: OSTEOSARCOMA, muscle spasms

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Bonsity, Forteo